Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V3FM
|
|||
| Drug Name |
Delpazolid
|
|||
| Synonyms |
LCB01-0371; 1219707-39-7; UNII-43EP6XV33E; LCB-01-0371; LCB-010371; 43EP6XV33E; (5R)-3-[3-Fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one; (5R)-3-(3-Fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(hydroxymethyl)-1,3-oxazolidin-2-one; (5R)-3-(3-Fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one; (5R)-3-[3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4-yl)phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one; (5R)-3-[3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4-yl)phenyl]-5-(hydroxymethyl)oxazolidin-2-one; Delpazolid (LCB01-0371); CHEMBL1673408; SCHEMBL11969210; GTPL10999; BCP25650; EX-A1715; ACN-053047; DB13077; SB18949; LCB-01,0371; 2-Oxazolidinone, 3-(4-(5,6-dihydro-1-methyl-1,2,4-triazin-4(1H)-yl)-3-fluorophenyl)-5-(hydroxymethyl)-, (5R)-; HY-100180; CS-0018175; Q27258646; (R)-3-(3-Fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pulmonary tuberculosis [ICD-11: 1B10.Z] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H17FN4O3
|
|||
| Canonical SMILES |
CN1CCN(C=N1)C2=C(C=C(C=C2)N3CC(OC3=O)CO)F
|
|||
| InChI |
1S/C14H17FN4O3/c1-17-4-5-18(9-16-17)13-3-2-10(6-12(13)15)19-7-11(8-20)22-14(19)21/h2-3,6,9,11,20H,4-5,7-8H2,1H3/t11-/m1/s1
|
|||
| InChIKey |
QLUWQAFDTNAYPN-LLVKDONJSA-N
|
|||
| CAS Number |
CAS 1219707-39-7
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02836483) A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.